Mackenzie Financial’s iBio IBIO Stock Holding History

Mackenzie Financial’s Portfolio IBIO Stock Details IBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-24	Closed	-$5K	–	1500
2022 Q1	$5K	Hold	24	–	–	﹤0.01%	1405
2021 Q4	$7K	Sell	24 -1	-4%	-$381	﹤0.01%	1424
2021 Q3	$13K	Buy	+25	New	+$15.6K	﹤0.01%	1428

Other funds holding IBIO

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Ergoteles New York $68.2M AUM 36.16% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Mackenzie Financial's IBIO Position: Q2 2022 in Review

Mackenzie Financial sold out of iBio (IBIO) in Q2 2022, closing a stake of 24 shares — an estimated $5K sold.

Mackenzie Financial first reported a position in IBIO in Q3 2021 and held it in 3 quarters. The position peaked at $13K in Q3 2021. 53 funds tracked by Wall St. Rank hold IBIO as of Q2 2022.

Mackenzie Financial reported no remaining iBio position as of Q2 2022 after selling out during the quarter.
Mackenzie Financial sold 24 iBio shares in Q2 2022, an estimated $5K.
Mackenzie Financial first reported a position in iBio in Q3 2021 and held it in 3 quarters.
Mackenzie Financial's iBio position peaked at $13K in Q3 2021.
53 funds tracked by Wall St. Rank held iBio as of Q2 2022.

Based on Mackenzie Financial's 13F filing for Q2 2022, filed 10 Aug 2022.